216 related articles for article (PubMed ID: 21797754)
1. Extracellular matrix powder protects against bleomycin-induced pulmonary fibrosis.
Manni ML; Czajka CA; Oury TD; Gilbert TW
Tissue Eng Part A; 2011 Nov; 17(21-22):2795-804. PubMed ID: 21797754
[TBL] [Abstract][Full Text] [Related]
2. Common and distinct mechanisms of induced pulmonary fibrosis by particulate and soluble chemical fibrogenic agents.
Dong J; Yu X; Porter DW; Battelli LA; Kashon ML; Ma Q
Arch Toxicol; 2016 Feb; 90(2):385-402. PubMed ID: 26345256
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10.
Tager AM; Kradin RL; LaCamera P; Bercury SD; Campanella GS; Leary CP; Polosukhin V; Zhao LH; Sakamoto H; Blackwell TS; Luster AD
Am J Respir Cell Mol Biol; 2004 Oct; 31(4):395-404. PubMed ID: 15205180
[TBL] [Abstract][Full Text] [Related]
4. Megakaryoblastic leukemia-1 is required for the development of bleomycin-induced pulmonary fibrosis.
Bernau K; Ngam C; Torr EE; Acton B; Kach J; Dulin NO; Sandbo N
Respir Res; 2015 Mar; 16(1):45. PubMed ID: 25885656
[TBL] [Abstract][Full Text] [Related]
5. The molecular mechanisms of extracellular matrix-derived hydrogel therapy in idiopathic pulmonary fibrosis models.
Evangelista-Leite D; Carreira ACO; Nishiyama MY; Gilpin SE; Miglino MA
Biomaterials; 2023 Nov; 302():122338. PubMed ID: 37820517
[TBL] [Abstract][Full Text] [Related]
6. Necrostatin-1 Alleviates Bleomycin-Induced Pulmonary Fibrosis and Extracellular Matrix Expression in Interstitial Pulmonary Fibrosis.
Mou F; Mou C
Med Sci Monit; 2020 Feb; 26():e919739. PubMed ID: 32019905
[TBL] [Abstract][Full Text] [Related]
7. TIMP-1 is a key factor of fibrogenic response to bleomycin in mouse lung.
Manoury B; Caulet-Maugendre S; Guénon I; Lagente V; Boichot E
Int J Immunopathol Pharmacol; 2006; 19(3):471-87. PubMed ID: 17026855
[TBL] [Abstract][Full Text] [Related]
8. The transcription factor NRF2 protects against pulmonary fibrosis.
Cho HY; Reddy SP; Yamamoto M; Kleeberger SR
FASEB J; 2004 Aug; 18(11):1258-60. PubMed ID: 15208274
[TBL] [Abstract][Full Text] [Related]
9. Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model.
Shieh JM; Tseng HY; Jung F; Yang SH; Lin JC
Mediators Inflamm; 2019; 2019():7947596. PubMed ID: 31049028
[TBL] [Abstract][Full Text] [Related]
10. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
[TBL] [Abstract][Full Text] [Related]
11. Grape seed extract ameliorates bleomycin-induced mouse pulmonary fibrosis.
Liu Q; Jiang JX; Liu YN; Ge LT; Guan Y; Zhao W; Jia YL; Dong XW; Sun Y; Xie QM
Toxicol Lett; 2017 May; 273():1-9. PubMed ID: 28300665
[TBL] [Abstract][Full Text] [Related]
12. Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6.
Xu L; Yang D; Zhu S; Gu J; Ding F; Bian W; Rong Z; Shen C
Exp Lung Res; 2013 Aug; 39(6):241-8. PubMed ID: 23672275
[TBL] [Abstract][Full Text] [Related]
13. Fructose-1,6-bisphosphate prevents pulmonary fibrosis by regulating extracellular matrix deposition and inducing phenotype reversal of lung myofibroblasts.
Dias HB; de Oliveira JR; Donadio MVF; Kimura S
PLoS One; 2019; 14(9):e0222202. PubMed ID: 31509566
[TBL] [Abstract][Full Text] [Related]
14. The Integrin Inhibitor Cilengitide and Bleomycin-Induced Pulmonary Fibrosis : Cilengitide and Bleomycin-Induced Pulmonary Fibrosis.
Ritzenthaler JD; Zhang M; Torres-Gonzalez E; Roman J
Lung; 2020 Dec; 198(6):947-955. PubMed ID: 33146772
[TBL] [Abstract][Full Text] [Related]
15. Particulate Matter Increases the Severity of Bleomycin-Induced Pulmonary Fibrosis through KC-Mediated Neutrophil Chemotaxis.
Cheng IY; Liu CC; Lin JH; Hsu TW; Hsu JW; Li AF; Ho WC; Hung SC; Hsu HS
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905700
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction.
Dackor RT; Cheng J; Voltz JW; Card JW; Ferguson CD; Garrett RC; Bradbury JA; DeGraff LM; Lih FB; Tomer KB; Flake GP; Travlos GS; Ramsey RW; Edin ML; Morgan DL; Zeldin DC
Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L645-55. PubMed ID: 21856819
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta.
Oga T; Matsuoka T; Yao C; Nonomura K; Kitaoka S; Sakata D; Kita Y; Tanizawa K; Taguchi Y; Chin K; Mishima M; Shimizu T; Narumiya S
Nat Med; 2009 Dec; 15(12):1426-30. PubMed ID: 19966781
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice.
Chen XH; Sun RS; Hu JM; Mo ZY; Yang ZF; Jin GY; Guan WD; Zhong NS
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):146-53. PubMed ID: 18785980
[TBL] [Abstract][Full Text] [Related]
19. Characterization of lung stem cell niches in a mouse model of bleomycin-induced fibrosis.
Banerjee ER; Henderson WR
Stem Cell Res Ther; 2012 May; 3(3):21. PubMed ID: 22643035
[TBL] [Abstract][Full Text] [Related]
20. Protective role of rhapontin in experimental pulmonary fibrosis in vitro and in vivo.
Tao L; Cao J; Wei W; Xie H; Zhang M; Zhang C
Int Immunopharmacol; 2017 Jun; 47():38-46. PubMed ID: 28364627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
